从实体瘤样本中获得全基因组拷贝数变异(CNV)和杂合性丢失(LOH)信息可是个重大的挑战,因为FFPE 样本高度降解,且DNA 数量有限。传统的FISH 和PCR 方法只关注单个位点,且分辨率不高。尽管新一代测序技术分析CNV 已经有一定进展,但仍需靶向富集和深度覆盖,才能获得异质FFPE 样本的拷贝数信息。

全新的OncoScan FFPE 试剂盒利用独特的分子倒置探针(MIP)技术,能够快速经济地分析来自FFPE 样本的少量的高度降解的DNA,让实体瘤分析向前迈进了一大步。这一新产品仅需80 ng 起始DNA,在短短48 小时内完成全基因组范围的实体瘤拷贝数分析,且在全基因组内大约900 个已知的癌基因进行高密度覆盖,同时可以提供临床相关的获得性突变的数据。

Oncoscan 已在多家全球知名肿瘤研究中心试验运行,包括MD Anderson 肿瘤中心,Memorial Sloan Kettering 肿瘤中心等,实验结果与FISH 验证的结果99% 以上一致。同时OncoScan 将运用在University Health Network (Canada's largest research hospital) 和 Ontario 肿瘤研究所的230 万美金的合作项目,用于发现非小细胞肺癌(NSCLC)的治疗靶点。

OncoScan Nexus Express Software Whole-Genome View

"We performed testing of the new OncoScan™ FFPE Assay Kit at ARUP and were able to detect FISH-confirmed aberrations in several key cancer genes including ERBB2, MDM2, EGFR, and MYC suggesting that OncoScan FFPE Assay Kit can be considered a viable, higher resolution and higher specificity alternative to FISH testing for confirmation of cancer gene aberrations in solid tumor tissue. Because OncoScan FFPE Assay Kit has whole-genome resolution, we also obtained valuable incremental copy number aberrations in these samples."

Sarah South, PhD, Medical Director, Cytogenetics, Genomic Microarray and Genetic Processing Laboratories, ARUP Laboratories

Sarah South, PhD

"We believe that the OncoScan assay is a robust platform for the rapid discovery and validation of novel prognostic copy number signatures that may also be useful in a clinical setting for the detection of specific gains in tumors as markers for patient stratification."

Professor Torsten Pietsch, MD, PhD, Institute of Neuropathology, University of Bonn, Germany